Palivizumab Articles
PDL BioPharma to pay MedImmune $92.5 million to resolve patent disputes; Mylan debuts generic Vfend
17 February 2011
AstraZeneca sees strong earnings and revenue growth in2009 but a slowdown in 4th qtr
28 January 2010
PDL expects 18% rise in 2nd-qtr revenues
9 June 2009
PDL returns to profit on sales up 31%
16 March 2009
Genentech settles Cabilly patent case
16 June 2008
PDL's 1st-qtr 2008 net loss triples to $62M
26 May 2008
UPDATE: MedImmune's biologics capabilities to boost AstraZeneca's flagging pipeline
17 December 2007
Early RSV prevention offers economic benefits
5 November 2007
MedImmune's 1st-qtr profit triples on Synagis
21 May 2007
MedImmune expects 170% leap in 1st-qtr EPS
16 April 2007
MedImmune's 4th-qtr income rises 7%
19 February 2007
US Supreme Court decision "will alter structure of future deals"
22 January 2007
US Supreme Court's MedImmune ruling eases patent challenges
15 January 2007
MedImmune's 3rd-qtr loss down 13% $55.8M
6 November 2006
MedImmune's 2nd-qtr 2006 loss deepens 43%
31 July 2006
MedImmune sees its 1st-qtr 2006 sales fall
15 May 2006
Numax reduces RSV in Ph 1 trial
12 September 2005
MedImmune to regain Synagis promotion rights from Abbott
5 September 2005
MedImmune's Numax sees good Ph I/II
30 May 2005
MedImmune reaches $0.45 quarter-year EPS
22 April 2005
MedImmune and Abbott expand ex-US agreement
7 March 2005
MedImmune posts 15% rise in sales
14 February 2005
MedImmune initiates Ph III study of Numax
8 November 2004
MedImmune's 3rd-qtr loss grows four-fold
1 November 2004
FDA OK for liquid version of Synagis
2 August 2004
MedImmune's 2nd-qtr plunges into loss
2 August 2004
MedImmune plans for $2B sales in 2009
8 March 2004
MedImmune files Numax IND
6 October 2003
Colorado Medicaid sets eight-drug limit
5 May 2003
MedImmune posts major losses
6 May 2002
MedImmune reports new Synagis data
25 October 2001
MedImmune licenses HuMAb-Mouse tech from Medarex
15 June 2000
Synagis launched in UK for RSV prevention
24 September 1999
EC approves Abbott/MedImmune's Synagis
2 September 1999
CPMP backs Synagis for RSV prevention
24 May 1999
HMO "not dropping Prozac or Prilosec"
21 April 1999
US biotech drug sales to grow 13% pa to 2002
29 March 1999
Abbott, MedImmune File For Synagis In EU
12 August 1998
FDA Clears MedImmune's Synagis For RSV
22 June 1998
US Biotech Ends Year "Slightly Ahead" Of 1996
21 January 1998
MedImmune Makes $66.3 Mill Placement
14 January 1998
MedImmune Files For MEDI-493 Approval
6 January 1998
Abbott Licenses RSV Ab
11 December 1997
Showing 1-67 of 67 articles
- 1
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- Neovacs moving forward in rheumatoid arthritis, say analysts
